EO-2463 is under clinical development by Enterome Bioscience and currently in Phase II for Marginal Zone B-cell Lymphoma. According to GlobalData, Phase II drugs for Marginal Zone B-cell Lymphoma have a 48% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how EO-2463’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
EO-2463 overview
EO-2463 is under development for the treatment of B-cell malignancies like B-cell leukemias and follicular lymphoma (FL) or marginal zone lymphoma (MZL). The drug candidate is next-generation microbiome-derived vaccine acts by targeting novel antigens (CD20, CD22, CD37 and BAFF-R) named onco-mimics. The drug candidate is developed based on OncoMimics platform. It is administered through subcutaneous route.
Enterome Bioscience overview
Enterome Bioscience (Enterome) is a clinical-stage biopharmaceutical company that develops immunomodulatory drugs for the treatment of cancer and immune diseases. The company’s pipeline products include memory T cell therapy and bioactives. Its pipeline candidates treat EO2401 +nivolumab, recurrent glioblastoma; EO2463, B-cell malignancies; EO2040, CRC ctDNA MRD; EO4010, CRC; EB1010, IBD and food allergy; EA300, food allergy. Its brands include OncoMimics, EndoMimics and AllerMimics. Enterome is headquartered in Paris, Ile-de-France, France.
For a complete picture of EO-2463’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
